NCT07643623

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

← Hub

Registry fields

Overall status: RECRUITING
Conditions: Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Study type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab, Ipilimumab N01, Oxaliplatin for injection, Ipilimumab N01 Placebo
Lead sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (INDUSTRY)

Cached at: 2026-08-15 01:35:52

View on ClinicalTrials.gov

Brief summary

This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report